Methotrexate treatment
( DrugBank: Methotrexate / KEGG DRUG: Methotrexate )
2 diseases
41. 巨細胞性動脈炎
臨床試験数 : 131 / 薬物数 : 139 - (DrugBank : 36) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 125
Showing 1 to 3 of 3 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03892785 (ClinicalTrials.gov) | January 27, 202020200127 | 26/3/201920190326 | MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial MEthotrexateVersus TOcilizumab for Treatmentof GIant Cell Arteritis: a Multicenter, Randomized, Cont ... | MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial MEthotrexateVersus TOcilizumab for Treatmentof GIant Cell Arteritis: a Multicenter, Randomized, Cont ... | Giant Cell Arteritis | Drug: Prednisone treatment;Drug: Tocilizumab treatment;Drug: Methotrexate treatment;Other: Questionnaires;Biological: Blood samples Drug: Prednisone treatment;Drug: Tocilizumab treatment;Drug: Methotrexate treatment;Other: Questionn ... | Centre Hospitalier Universitaire Dijon | NULL | Recruiting | 50 Years | N/A | All | 230 | Phase 3 | France |
2 | EUCTR2018-002826-22-FR (EUCTR) | 07/03/201920190307 | 21/11/201820181121 | MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial - METOGIA MEthotrexateversus TOcilizumab for treatmentof GIant cell Arteritis: a multicenter, randomized, cont ... | MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial - METOGIA MEthotrexateversus TOcilizumab for treatmentof GIant cell Arteritis: a multicenter, randomized, cont ... | MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20] MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ ... | Trade Name: METOJECT Trade Name: RoActemra | CHU Dijon Bourgogne | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: no | 200 | Phase 3 | France | ||
3 | NCT00004686 (ClinicalTrials.gov) | February 199419940200 | 24/2/200020000224 | Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis Phase II Randomized Study of Glucocorticoids With or Without Methotrexatefor Treatmentof Giant Cell ... | Giant Cell Arteritis | Drug: methotrexate;Drug: prednisone | The Cleveland Clinic | NULL | Completed | 50 Years | N/A | Both | 300 | Phase 2 | NULL |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
Showing 1 to 10 of 530 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT05604885 (ClinicalTrials.gov) | November 30, 202220221130 | 31/10/202220221031 | A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate A Dose-range Study of the Safety and Efficacy of Treatmentin Adult Rheumatoid Arthritis Patients Wit ... | A Two-part, Randomized, Double-blind, Multi-center, Placebo-controlled Study of the Dose-range, Safety and Efficacy of 4 and 12 Weeks of Treatment With AP1189 in Adult Rheumatoid Arthritis (RA) Patients With an Inadequate Response to Methotrexate (MTX) Alone - (RESOLVE) A Two-part, Randomized, Double-blind, Multi-center, Placebo-controlled Study of the Dose-range, Safe ... | Rheumatoid Arthritis | Drug: AP1189, 60 mg;Drug: AP1189, 80 mg;Drug: AP1189, 100 mg;Drug: Placebo | SynAct Pharma Aps | NBCD A/S | Recruiting | 18 Years | 85 Years | All | 420 | Phase 2 | Moldova, Republic of |
2 | ITMCTR2200006086 | 2022-07-0120220701 | 2022-06-1020220610 | Multicenter randomized double-blind clinical trial of Qufeng Zhitong Capsule combined with Methotrexate tablets in the treatment of rheumatoid arthritis Multicenter randomized double-blind clinical trial of Qufeng Zhitong Capsule combined with Methotrex ... | Multicenter randomized double-blind clinical trial of Qufeng Zhitong Capsule combined with Methotrexate tablets in the treatment of rheumatoid arthritis Multicenter randomized double-blind clinical trial of Qufeng Zhitong Capsule combined with Methotrex ... | rheumatoid arthritis | matched group:Methotrexate tablet + qufeng analgesic capsule simulato;experimental group:Methotrexate tablet + qufeng analgesic capsule; matched group:Methotrexatetablet + qufeng analgesic capsule simulato;experimental group:Methotrexate ... | Guang 'anmen Hospital, China Academy of Traditional Chinese Medicine | NULL | Pending | 18 | 75 | Both | matched group:100;experimental group:100; | Phase 4 | China |
3 | NCT05363891 (ClinicalTrials.gov) | June 15, 202220220615 | 2/5/202220220502 | Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis | Phase II, Double-blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis Phase II, Double-blind, Placebo-Controlled, Randomized Trial Examining Natrunix in Combination With ... | Rheumatoid Arthritis | Drug: Natrunix;Drug: Placebo | XBiotech, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 150 | Phase 2 | NULL |
4 | NCT05363917 (ClinicalTrials.gov) | June 15, 202220220615 | 2/5/202220220502 | Natrunix Versus Methotrexate in Rheumatoid Arthritis | Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Natrunix Versus Methotrexate (+Folate) for the Treatment of Rheumatoid Arthritis Phase II Double-Blinded, Placebo-Controlled Randomized Study Examining the Safety and Efficacy of Na ... | Rheumatoid Arthritis | Drug: Natrunix with MTX placebo (+folate);Drug: Natrunix placebo with MTX (+folate) | XBiotech, Inc. | NULL | Not yet recruiting | 18 Years | N/A | All | 150 | Phase 2 | NULL |
5 | NCT05245448 (ClinicalTrials.gov) | February 22, 202220220222 | 22/1/202220220122 | Tetrandrine in the Treatment of Rheumatoid Arthritis | Comparing the Efficacy of Tetrandrine Combined With Methotrexate and Methotrexate Alone in the Treatment of Rheumatoid arthritis---a Randomized, Double-blinded, Placebo-controlled, Multicenter Study Comparing the Efficacy of Tetrandrine Combined With Methotrexateand MethotrexateAlone in the Treatme ... | Rheumatoid Arthritis | Drug: Tetrandrine;Drug: Placebo | Peking University People's Hospital | NULL | Not yet recruiting | 18 Years | 65 Years | All | 240 | N/A | China |
6 | EUCTR2020-000350-96-DE (EUCTR) | 11/01/202220220111 | 07/07/202120210707 | Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and who did not respond well to methotrexate Efficacy of Abatacept vs Adalimumab in Early, Autoantibody positive Rheumatoid Arthritis (RA) and wh ... | A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have Shared Epitope HLA Class II Risk Alleles and Have an Inadequate Response to Methotrexate A Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatmentwith Subcutaneous ... | Rheumatoid Arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Rheumatoid Arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ... | Trade Name: Orencia Product Name: Abatacept Product Code: BMS-188667 INN or Proposed INN: ABATACEPT Trade Name: Humira INN or Proposed INN: ADALIMUMAB Trade Name: Orencia Product Name: Abatacept Product Code: BMS-188667 INN or Proposed INN: ABATACEPT Trad ... | Bristol-Myers Squibb International Corporation | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 3 | United States;Czechia;Taiwan;Spain;United Kingdom;Italy;Switzerland;France;Czech Republic;Mexico;Argentina;Poland;Australia;Germany;Netherlands;Japan;Sweden United States;Czechia;Taiwan;Spain;United Kingdom;Italy;Switzerland;France;Czech Republic;Mexico;Arg ... | ||
7 | ChiCTR2200055292 | 2022-01-0420220104 | 2022-01-0520220105 | Correlation between the changes of serum cytokines and immune cell subsets levels and curative effect in patients with active rheumatoid arthritis before and after Yisaipu treatment Correlation between the changes of serum cytokines and immune cell subsets levels and curative effec ... | Correlation between the changes of serum cytokines and immune cell subsets levels and curative effect in patients with active rheumatoid arthritis before and after Yisaipu treatment Correlation between the changes of serum cytokines and immune cell subsets levels and curative effec ... | Rheumatoid Arthritis | Experimental group:Yisaipu combined with methotrexate and folic acid; | Peking University People's Hospital | NULL | Recruiting | 18 | 65 | Both | Experimental group:140; | Phase 4 | China |
8 | NCT05626348 (ClinicalTrials.gov) | December 22, 202120211222 | 15/11/202220221115 | The Clinical Efficacy of Immunomodulators in RA Patients | The Clinical Study to Observe the Efficacy and Safety of Immunomodulators in Rheumatoid Arthritis Patients for 6 Months Treatment in China The Clinical Study to Observe the Efficacy and Safety of Immunomodulators in Rheumatoid Arthritis Pa ... | Arthritis, Rheumatoid | Drug: Iguratimod;Drug: Methotrexate;Drug: Adalimumab Injection;Drug: Leflunomide;Drug: Hydroxychloroquine Drug: Iguratimod;Drug: Methotrexate;Drug: Adalimumab Injection;Drug: Leflunomide;Drug: Hydroxychloro ... | Qilu Hospital of Shandong University | NULL | Recruiting | 18 Years | 80 Years | All | 400 | Phase 4 | China |
9 | ChiCTR2100053999 | 2021-12-0120211201 | 2021-12-0620211206 | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatmentof Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLin ... | Clinical Study on Treatment of Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLing Zhiwang Prescription Clinical Study on Treatmentof Damp Heat Stagnation Syndrome of Rheumatoid Arthritis by SiMiaoXiaoLin ... | Rheumatism | Experimental group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate + folic acid tablets;Control group:methotrexate + folic acid tablets; Experimental group:Simiaoxiaoling Zhiwang Decoction (granule) + methotrexate+ folic acid tablets;Con ... | Yunnan Hospital of Traditional Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | Experimental group:36;Control group:36; | China | |
10 | ChiCTR2100054305 | 2021-12-0120211201 | 2021-12-1320211213 | Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixed syndrome of cold and heat Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatmentof RA with mixed ... | Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatment of RA with mixed syndrome of cold and heat Observation on the clinical efficacy of Jiawei Qianyang Fengsui Dan in the treatmentof RA with mixed ... | Rheumatoid Arthritis | Treatment group:Modified Qianyang Fengsui Dan + Methotrexate Tablets + Folic Acid Tablets;Control group:Methotrexate + Folic Acid; Treatmentgroup:Modified Qianyang Fengsui Dan + MethotrexateTablets + Folic Acid Tablets;Control grou ... | Yunnan Provincial Hospital of Traditional Chinese Medicine | NULL | Recruiting | 18 | 70 | Both | Treatment group:36;Control group:36; | China |